Dalpiciclib Plus Endocrine Therapy Improves Early HR+/HER2– Breast Cancer Outcomes
This phase 3 DAWNA‑A trial (NCT04842617) was conducted to determine whether adjuvant dalpiciclib enhances survival when combined with endocrine therapy (ET) in hormone receptor‑positive (HR+), HER2‑negative early breast cancer. Phase 3 DAWNA‑A randomized 5,274 HR+/ HER2– early breast cancer patients to dalpiciclib + ET (n = 2,640) or placebo + ET (n = 2,634). At […]
Nadunolimab Plus Chemotherapy Improves Survival in IL1RAP‑High Metastatic PDAC
The study analysis evaluated the efficacy of nadunolimab— a fully humanized Fc enhanced IgG1 monoclonal antibody targeting interleukin 1 receptor accessory protein (IL1RAP)—in combination with gemcitabine and nab paclitaxel for previously untreated, metastatic pancreatic ductal adenocarcinoma (PDAC) exhibiting elevated IL1RAP expression. The US Food and Drug Administration granted fast track designation based on these findings. […]
Dostarlimab–Chemotherapy Improves Quality-Adjusted and Overall Survival in Endometrial Cancer
This randomized, double‑blind, placebo‑controlled trial assessed whether adding dostarlimab to standard carboplatin–paclitaxel chemotherapy improves quality‑adjusted and overall survival in primary advanced or recurrent endometrial carcinoma. A total of 487 patients were randomized (241 dostarlimab; 246 placebo). Subjects received six 21‑day cycles of dostarlimab or placebo alongside carboplatin (AUC 5–6) and paclitaxel (175 mg/m²), followed by […]
Avacopan Reduces Adverse Events in ANCA-Associated Vasculitis Treatment
The pooled analysis aimed to evaluate the safety profile of avacopan, a complement C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Data were aggregated from two phase 2 trials (NCT01363388, NCT02222155) and one phase 3 trial (NCT02994927), encompassing 439 participants (239 avacopan; […]